Clinical Studies Sponsored by Sangamo Therapeutics

Safety of CERE-120 (AAV2-NTN) in Subjects With Idiopathic Parkinson's Disease

Stem Cell Mobilization in Diabetic Neuropathy Subjects Receiving SB-509

CERE-110 in Subjects With Mild to Moderate Alzheimer's Disease

Clinical Trial of SB-509-0401 in Subjects With Diabetic Neuropathy

Clinical Trial of SB-509 in Subjects With Diabetic Neuropathy

Clinical Trial of SB-509 in Subjects With Diabetic Neuropathy

Clinical Trial of SB-509 in Subjects With Amyotrophic Lateral Sclerosis (ALS)

Ascending Dose Study of Genome Editing by Zinc Finger Nuclease Therapeutic SB-FIX in Subjects With Severe Hemophilia B

Clinical Trial of SB-509 in Subjects With Diabetic Neuropathy

Phase 1 Dose Escalation Study of Autologous T-cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases in HIV-Infected Patients

A Study to Assess the Safety, Tolerability, and Efficacy of ST-400 for Treatment of Transfusion-Dependent Beta-thalassemia (TDT)

Long Term Follow-up (LTFU) of Subjects Who Received SB-318, SB-913, or SB-FIX

Ascending Dose Study of Genome Editing by the Zinc Finger Nuclease (ZFN) Therapeutic SB-913 in Subjects With MPS II

Double-Blind, Multicenter, Sham Surgery Controlled Study of CERE-120 in Subjects With Idiopathic Parkinson's Disease

Study of Autologous T-cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases in HIV-Infected Subjects

Long-Term Follow-Up of TX200-TR101 (STEADFAST Long Term)

Long-Term Follow-up of Subjects Who Were Treated With ST-920

Randomized, Controlled Study Evaluating CERE-110 in Subjects With Mild to Moderate Alzheimer's Disease

Safety and Efficacy of CERE-120 in Subjects With Parkinson's Disease

Repeat Doses of SB-728mR-T After Cyclophosphamide Conditioning in HIV-Infected Subjects on HAART

Dose Escalation Study of Cyclophosphamide in HIV-Infected Subjects on HAART Receiving SB-728-T